Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC).

被引：4
|
作者：
Verheijden, Gijs
Beusker, Patrick
Ubink, Ruud
van der Lee, Miranda
Groothuis, Patrick
Goedings, Peter J.
Egging, David
Mattaar, Ellen
Timmers, Macro
Dokter, Wim
机构：
[1] Synthon Biopharmaceut BV, Nijmegen, Netherlands
[2] Synthon BV, Nijmegen, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
626
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SYD985, a novel HER2-targeting antibody-drug conjugate in preclinical models for USC, both in vitro and in vivo.
    Black, Jonathan
    Lopez, Salvatore
    Cocco, Emiliano
    Bellone, Stefania
    Bonazzoli, Elena
    Schwab, Carlton
    English, Diana Peta-gay
    Goedings, Peter J.
    Beusker, Patrick
    van der Lee, Miranda
    Timmers, Marco
    Dokter, Wim
    Schwartz, Peter E.
    Santin, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985
    Elgersma, Ronald C.
    Coumans, Ruud G. E.
    Huijbregts, Tiji
    Menge, Wiro M. P. B.
    Joosten, John A. F.
    Spijker, Henri J.
    de Groot, Franciscus M. H.
    van der Lee, Miranda M. C.
    Ubink, Ruud
    van den Dobbelsteen, Diels J.
    Egging, David F.
    Dokter, Wim H. A.
    Verheijden, Gijs F. M.
    Lemmens, Jacques M.
    Timmers, C. Marco
    Beusker, Patrick H.
    MOLECULAR PHARMACEUTICS, 2015, 12 (06) : 1813 - 1835
  • [3] SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression
    Menderes, Gulden
    Bonazzoli, Elena
    Bellone, Stefania
    Black, Jonathan
    Predolini, Federica
    Pettinella, Francesca
    Masserdotti, Alice
    Zammataro, Luca
    Altwerger, Gary
    Buza, Natalia
    Hui, Pei
    Wong, Serena
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5836 - 5845
  • [4] SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
    Black, Jonathan
    Menderes, Gulden
    Bellone, Stefania
    Schwab, Carlton L.
    Bonazzoli, Elena
    Ferrari, Francesca
    Predolini, Federica
    De Haydu, Christopher
    Cocco, Emiliano
    Buza, Natalia
    Hui, Pei
    Wong, Serena
    Lopez, Salvatore
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Litkouhi, Babak
    Schwartz, Peter E.
    Goedings, Peter
    Beusker, Patrick H.
    van der Lee, Miranda M. C.
    Timmers, C. Marco
    Dokter, Wim H. A.
    Santin, Alessandro D.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1900 - 1909
  • [5] SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
    Menderes, Gulden
    Bonazzoli, Elena
    Bellone, Stefania
    Black, Jonathan
    Altwerger, Gary
    Masserdotti, Alice
    Pettinella, Francesca
    Zammataro, Luca
    Buza, Natalia
    Hui, Pei
    Ratner, Elena
    Litkouhi, Babak
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter
    Santin, Alessandro D.
    CANCER RESEARCH, 2017, 77
  • [6] SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
    Menderes, Gulden
    Bonazzoli, Elena
    Bellone, Stefania
    Black, Jonathan
    Altwerger, Gary
    Masserdotti, Alice
    Pettinella, Francesca
    Zammataro, Luca
    Buza, Natalia
    Hui, Pei
    Wong, Serena
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Huang, Gloria S.
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2017, 146 (01) : 179 - 186
  • [7] SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.
    Menderes, Gulden
    Bonazzoli, Elena
    Bellone, Stefania
    Black, Jonathan
    Altwerger, Gary
    Pettinella, Francesca
    Masserdotti, Alice
    Zammataro, Luca
    Buza, Natalia
    Hui, Pei
    Wong, Serena
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] In vitro and in vivo antitumor activity of SYD985, a novel HER2-targeting ADC: a comparison with T-DM1
    Dokter, Willem H. A.
    van der Lee, Miranda
    Groothuis, Patrick
    van Achterberg, Tanja
    Loosveld, Eline
    Jacobs, Danielle
    van der Vleuten, Monique
    Beusker, Patrick H.
    Hooftman, Leon
    Goedings, Peter
    Verheijden, Gijs
    Timmers, Marco
    CANCER RESEARCH, 2014, 74 (19)
  • [9] SYD985, a Novel HER2 Targeting Antibody-Drug-Conjugate, Demonstrates Remarkable Antitumor Activity in Carcinosarcoma.
    Black, Jonathan
    Schwab, Carlton
    Lopez, Salvatore
    Cocco, Emiliano
    Bellone, Stefania
    Bonazzoli, Elena
    Menderes, Gulden
    Goedings, Peter
    Beusker, Patric
    van der Lee, Miranda
    Timmers, Marco
    Dokter, Wim
    Litkouhi, Babak
    Silasi, Dan-Arin
    Ratner, Elena
    Azodi, Masoud
    Schwartz, Peter
    Santin, Alessandro
    REPRODUCTIVE SCIENCES, 2016, 23 : 180A - 180A
  • [10] SYD985, a novel HER2-targeting antibody-drug conjugate, shows strong antitumor activity in primary USC cell lines with low (1+) and moderate (2+) HER2/Neu expression
    Black, Jonathan D.
    Lopez, Salvatore
    Cocco, Emiliano
    Bellone, Stefania
    Bonazzoli, Elena
    Schwab, Carlton
    English, Diana
    Goedings, Peter
    Beusker, Patrick
    van der Lee, Miranda
    Timmers, Marco
    Dokter, Wim
    Rutherfor, Thomas
    Schwartz, Peter
    Santin, Alessandro
    CANCER RESEARCH, 2015, 75
12345